Diaceutics uses its data analysis and advisory services to make the development of precision medicines and their related diagnostic tests, more efficient and help pharma companies achieve a better return. The data itself is a highly valuable asset and significant time and investment would be required for a competitor to develop its own version of the technology and collect the data. This is a good business. The question is how much should be paid for the shares? On top of the £17m raised by the company, existing shareholders raised £3.75m from share sales. However, they went to a limited numbe...
